BRIEF—Biogen tells shareholders to reject the below-market mini-tender

20 May 2019

US biotech major Biogen has received notice of an unsolicited mini-tender offer by TRC Capital Corp to purchase up to 500,000 shares of Biogen’s common stock at a price of $216.25 per share in cash.

Biogen does not endorse TRC Capital’s unsolicited mini-tender offer and recommends that stockholders do not tender their shares in response to TRC Capital’s offer because the offer is at a price below the current market price for Biogen’s shares and subject to numerous conditions.

TRC Capital’s offer price is around 4.41% lower than the $226.23 closing share price of Biogen’s common stock on May 10, 2019, the last business day prior to the commencement of the offer.

The shares closed at $299.28 on Friday May 18.

The offer is for about 0.26% of the shares of Biogen common stock outstanding as of the May 13, 2019, offer date.

TRC Capital has made many similar mini-tender offers for shares of other companies.

Mini-tender offers seek to acquire less than 5%of a company’s shares outstanding, thereby avoiding many disclosure and procedural requirements of the US Securities and Exchange Commission (SEC) that apply to offers for more than five percent of a company’s shares outstanding.

As a result, mini-tender offers do not provide investors with the same level of protections as provided by larger tender offers under US securities laws.

Companies featured in this story

More ones to watch >